Preliminary results from SpectraCure’s prostate treatments
Preliminary results have been reported from the latest patient treatments in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital. A very clear treatment effect is seen on MR images in the treatment area, indicating destruction of the tumour, just like previously treated patients with the high […]
New patient treatment, phase 2 initiated
A patient was treated on Tuesday April 9th, 2019, in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital. The treatment was performed with SpectraCure's photodynamic therapy (PDT) method. The procedure went as expected and the patient is doing well. "It is gratifying that we are now […]
SpectraCure files for a new patent
SpectraCure has filed for a new patent to the European Patent Office, the patent covers a new technology to improve the company's IDOSE technology. The IDOSE technique is at the heart of the company's method of treating prostate cancer with photodynamic therapy (PDT). In short, the technique implies that the prostate tissue is monitored during […]
Status report for phase 2 study
SpectraCure has conducted a Phase 1 clinical trial for the treatment of patients with recurrent prostate cancer with the company's technology for photodynamic therapy (PDT). As previously announced, at the end of 2018, the company entered the final stage of planning for a subsequent phase 2 study. In early 2019, SpectraCure renewed certain contracts and […]
Final preparation for Phase 2 – SpectraCure extends contract with hospital in London
Prior to the upcoming Phase 2 study, SpectraCure has today extended the agreement with University College London Hospital (UCL) for two years. The agreement is intended to cover the entire phase 2 for treatment of patients with recurrent prostate cancer, using the company's photodynamic therapy (PDT) method. The purpose of the Phase 2 study is […]
SpectraCure AB Year-end report 1 January – 31 December 2018
Fourth quarter (1 October – 31 December 2018) Net sales for the quarter amounted to TSEK 0 (0). Operating profit (EBIT) was TSEK -3 249 (-2 599). Operating cash flow was TSEK -3 806 (-2 632). Profit after tax amounted to TSEK -3 242 (-2 599). Corresponding to SEK -0,04 (-0,04) per share. Full-year (1 […]
More results from Phase 1 study
Results of the evaluation of PSA values have been reported in the clinical phase 1 study that SpectraCure is currently running for treatment of patients with recurrent prostate cancer, using the company's photodynamic therapy (PDT) method. PSA (prostate-specific antigen) is a blood marker that can indicate the presence of a tumour in the prostate. The […]
Results from clinical study for patient 9 and 10
In SpectraCure’s Phase 1 study for treatment of patients with recurrent prostate cancer, preliminary results have been reported for the most recently treated patients. The treatment method, called photodynamic therapy (PDT), means that the patient is given a light-activated drug that accumulates in the tumour. When the cancerous tissue is illuminated using SpectraCure’s IDOSE technique, […]
SpectraCure receives prestigious grant from the Eurostars program
SpectraCure has been awarded an R&D grant of approximately SEK 5 million through the EU Eurostars program, to develop an advanced image management system to be used together with the company's IDOSE technology. The development project will be carried out together with the German company MedCom GmbH, which will also receive a grant. SpectraCure has […]
SpectraCure one step closer to Phase 2 after successful treatment effect in recent patients
SpectraCure will, as previously announced, enter a Phase 2 clinical trial in early 2019. This is a result of successful treatment effects seen in the most recently treated patients. A clear therapeutic effect is seen in these patients, with intended changes seen in the tumor region thanks to SpectraCure’s method based on photodynamic tumor treatment […]
